News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
698,802 Results
Type
Article (39690)
Company Profile (247)
Press Release (658865)
Multimedia
Podcasts (49)
Webinars (12)
Section
Business (204164)
Career Advice (2007)
Deals (35418)
Drug Delivery (95)
Drug Development (81044)
Employer Resources (172)
FDA (16180)
Job Trends (14857)
News (345182)
Policy (32538)
Tag
Academia (2554)
Accelerated approval (5)
Adcomms (20)
Allergies (85)
Alliances (49431)
ALS (88)
Alzheimer's disease (1378)
Antibody-drug conjugate (ADC) (124)
Approvals (16185)
Artificial intelligence (253)
Autoimmune disease (21)
Automation (16)
Bankruptcy (360)
Best Places to Work (11636)
BIOSECURE Act (19)
Biosimilars (105)
Biotechnology (175)
Bladder cancer (78)
Brain cancer (27)
Breast cancer (278)
Cancer (2256)
Cardiovascular disease (174)
Career advice (1676)
Career pathing (30)
CAR-T (151)
Cell therapy (422)
Cervical cancer (19)
Clinical research (65986)
Collaboration (832)
Company closure (1)
Compensation (533)
Complete response letters (19)
COVID-19 (2588)
CRISPR (40)
C-suite (241)
Cystic fibrosis (100)
Data (2205)
Decentralized trials (2)
Denatured (18)
Depression (43)
Diabetes (270)
Diagnostics (6369)
Digital health (18)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (120)
Drug pricing (98)
Drug shortages (25)
Duchenne muscular dystrophy (93)
Earnings (86628)
Editorial (37)
Employer branding (21)
Employer resources (146)
Events (112393)
Executive appointments (722)
FDA (17442)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (747)
Gene editing (104)
Generative AI (19)
Gene therapy (301)
GLP-1 (708)
Government (4416)
Grass and pollen (4)
Guidances (67)
Healthcare (18814)
Huntington's disease (23)
IgA nephropathy (27)
Immunology and inflammation (115)
Indications (29)
Infectious disease (2730)
Inflammatory bowel disease (137)
Inflation Reduction Act (8)
Influenza (51)
Intellectual property (96)
Interviews (311)
IPO (16507)
IRA (40)
Job creations (3630)
Job search strategy (1422)
Kidney cancer (10)
Labor market (38)
Layoffs (467)
Leadership (17)
Legal (7909)
Liver cancer (75)
Lung cancer (320)
Lymphoma (154)
Machine learning (7)
Management (58)
Manufacturing (304)
MASH (67)
Medical device (13377)
Medtech (13382)
Mergers & acquisitions (19455)
Metabolic disorders (685)
Multiple sclerosis (80)
NASH (16)
Neurodegenerative disease (88)
Neuropsychiatric disorders (27)
Neuroscience (1913)
NextGen: Class of 2025 (6512)
Non-profit (4480)
Now hiring (39)
Obesity (364)
Opinion (204)
Ovarian cancer (75)
Pain (87)
Pancreatic cancer (83)
Parkinson's disease (148)
Partnered (21)
Patents (233)
Patient recruitment (112)
Peanut (46)
People (57299)
Pharmaceutical (63)
Pharmacy benefit managers (18)
Phase I (20557)
Phase II (29056)
Phase III (21649)
Pipeline (1203)
Policy (138)
Postmarket research (2563)
Preclinical (8738)
Press Release (64)
Prostate cancer (106)
Psychedelics (30)
Radiopharmaceuticals (246)
Rare diseases (378)
Real estate (5907)
Recruiting (65)
Regulatory (22281)
Reports (46)
Research institute (2320)
Resumes & cover letters (349)
Rett syndrome (5)
RNA editing (5)
RSV (42)
Schizophrenia (69)
Series A (130)
Series B (84)
Service/supplier (11)
Sickle cell disease (52)
Special edition (14)
Spinal muscular atrophy (147)
Sponsored (29)
Startups (3576)
State (2)
Stomach cancer (13)
Supply chain (68)
Tariffs (40)
The Weekly (29)
Vaccines (688)
Venture capitalists (41)
Weight loss (234)
Women's health (35)
Worklife (16)
Date
Today (143)
Last 7 days (899)
Last 30 days (2596)
Last 365 days (32755)
2025 (10700)
2024 (35218)
2023 (40076)
2022 (51173)
2021 (55710)
2020 (54083)
2019 (46538)
2018 (35018)
2017 (32109)
2016 (31480)
2015 (37552)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (718)
Alabama (53)
Alaska (7)
Arizona (232)
Arkansas (13)
Asia (37838)
Australia (6184)
California (6124)
Canada (2013)
China (523)
Colorado (266)
Connecticut (274)
Delaware (148)
Europe (81240)
Florida (911)
Georgia (206)
Idaho (57)
Illinois (535)
India (25)
Indiana (307)
Iowa (11)
Japan (162)
Kansas (104)
Kentucky (24)
Louisiana (10)
Maine (62)
Maryland (894)
Massachusetts (4567)
Michigan (220)
Minnesota (390)
Mississippi (2)
Missouri (81)
Montana (27)
Nebraska (25)
Nevada (63)
New Hampshire (63)
New Jersey (1726)
New Mexico (28)
New York (1745)
North Carolina (966)
North Dakota (8)
Northern California (2680)
Ohio (204)
Oklahoma (14)
Oregon (34)
Pennsylvania (1375)
Puerto Rico (12)
Rhode Island (33)
South America (1096)
South Carolina (23)
South Dakota (1)
Southern California (2299)
Tennessee (101)
Texas (906)
United States (23103)
Utah (180)
Virginia (145)
Washington D.C. (61)
Washington State (550)
West Virginia (3)
Wisconsin (54)
698,802 Results for "lensar inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Alcon Agrees to Acquire LENSAR, Inc.
March 25, 2025
·
9 min read
Deals
LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”) today announced that a majority of the independent members of LENSAR’s board of directors granted three newly-hired non-executive employees stock options to purchase an aggregate of 2,150 shares of the Company’s common stock.
June 3, 2024
·
1 min read
Press Releases
LENSAR Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update
February 28, 2025
·
19 min read
Press Releases
LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - March 3, 2025
March 3, 2025
·
1 min read
Press Releases
LENSAR to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 27, 2025
February 19, 2025
·
1 min read
BioMidwest
LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 01, 2024
LENSAR, Inc. announced that a majority of the independent members of LENSAR’s board of directors granted two newly-hired non-executive employees stock options to purchase an aggregate of 875 shares of the Company’s common stock.
May 1, 2024
·
1 min read
Business
LENSAR Reports First Quarter 2024 Results and Provides Business Update
LENSAR, Inc. today announced financial results for the quarter ended March 31, 2024 and provided an update on key operational initiatives.
May 9, 2024
·
13 min read
LENSAR to Participate in the 2024 Leerink Partners Healthcare Crossroads Conference
LENSAR, Inc. today announced that Nick Curtis, Chief Executive Officer, will participate in a Fireside Chat at the 2024 Leerink Partners Healthcare Crossroads Conference on Wednesday, May 29, 2024, at 1:40 p.m. CT in Austin, TX.
May 23, 2024
·
1 min read
Press Releases
LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - February 3, 2025
February 4, 2025
·
1 min read
BioMidwest
LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - April 01, 2024
LENSAR, Inc. announced that a majority of the independent members of LENSAR’s board of directors granted three newly-hired non-executive employees stock options to purchase an aggregate of 1,425 shares of the Company’s common stock.
April 1, 2024
·
1 min read
1 of 69,881
Next
